

Russell Vang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11962553/publications.pdf>

Version: 2024-02-01

129
papers

9,356
citations

28190

55
h-index

40881

93
g-index

131
all docs

131
docs citations

131
times ranked

7837
citing authors

#	ARTICLE	IF	CITATIONS
1	Ovarian Combined Serous Borderline Tumor/Low-grade Serous Carcinoma and Mesonephric-like Lesion: Report of 2 Cases With New Observations. <i>International Journal of Gynecological Pathology</i> , 2023, 42, 182-191.	0.9	8
2	Mucinous Tumor Coexisting With Mesonephric-like Proliferation/Tumor in the Ovary. <i>American Journal of Surgical Pathology</i> , 2022, 46, 1095-1105.	2.1	11
3	Verrucous Squamous Hyperplasia of the Urinary Bladder. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, , .	1.2	0
4	Gastrointestinal Stromal Tumors Mimicking Gynecologic Disease: Clinicopathological Analysis of 20 Cases. <i>Diagnostics</i> , 2022, 12, 1563.	1.3	2
5	Pathologist Concordance for Ovarian Carcinoma Subtype Classification and Identification of Relevant Histologic Features Using Microscope and Whole Slide Imaging. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1516-1525.	1.2	5
6	Endosalpingiosis Is Negative for GATA3. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1448-1452.	1.2	2
7	Coexistence of Conventional Leiomyoma, Fumarate Hydratase-deficient Atypical Leiomyoma, and Perivascular Epithelioid Cell Tumor in a Uterus: A Case Study. <i>International Journal of Gynecological Pathology</i> , 2021, 40, 134-140.	0.9	2
8	Selection of Representative Histologic Slides in Interobserver Reproducibility Studies: Insights from Expert Review for Ovarian Carcinoma Subtype Classification. <i>Journal of Pathology Informatics</i> , 2021, 12, 15.	0.6	0
9	Selection of Representative Histologic Slides in Interobserver Reproducibility Studies: Insights from Expert Review for Ovarian Carcinoma Subtype Classification. <i>Journal of Pathology Informatics</i> , 2021, 12, 15.	0.8	2
10	Intratumoral Heterogeneity Accounts for Apparent Progression of Noninvasive Serous Tumors to Invasive Low-grade Serous Carcinoma: A Study of 30 Low-grade Serous Tumors of the Ovary in 18 Patients With Peritoneal Carcinomatosis. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 43-54.	0.9	16
11	Prevalence of somatic and germline mutations of <i>Fumarate hydratase</i> in uterine leiomyomas from young patients. <i>Histopathology</i> , 2020, 76, 354-365.	1.6	20
12	Ovarian Intermediate Trophoblastic Tumors. <i>American Journal of Surgical Pathology</i> , 2020, 44, 516-525.	2.1	4
13	Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report. <i>Gynecologic Oncology Reports</i> , 2020, 32, 100555.	0.3	2
14	Immune checkpoint status and tumor microenvironment in vulvar squamous cell carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 93-102.	1.4	15
15	Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: A nationwide study. <i>International Journal of Cancer</i> , 2020, 147, 990-995.	2.3	11
16	An Epithelioid Smooth Muscle Neoplasm Mimicking a Signet Ring Cell Carcinoma in the Ovary. <i>International Journal of Gynecological Pathology</i> , 2019, 38, 464-469.	0.9	3
17	Diseases of the Fallopian Tube and Paratubal Region. , 2019, , 649-714.		3
18	Germ Cell Tumors of the Ovary. , 2019, , 1047-1124.		4

#	ARTICLE	IF	CITATIONS
19	Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva. <i>Human Pathology</i> , 2019, 92, 67-80.	1.1	17
20	Lineage-Specific Alterations in Gynecologic Neoplasms with Choriocarcinomatous Differentiation: Implications for Origin and Therapeutics. <i>Clinical Cancer Research</i> , 2019, 25, 4516-4529.	3.2	22
21	Cytomorphologic and molecular analyses of fallopian tube fimbrial brushings for diagnosis of serous tubal intraepithelial carcinoma. <i>Cancer Cytopathology</i> , 2019, 127, 192-201.	1.4	1
22	Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1462-1472.	2.1	33
23	Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions. <i>Journal of Pathology</i> , 2019, 248, 41-50.	2.1	84
24	Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 110-124.	3.2	102
25	BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma. <i>Oncotarget</i> , 2019, 10, 6870-6878.	0.8	10
26	Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix. <i>American Journal of Surgical Pathology</i> , 2018, 42, 750-760.	2.1	65
27	Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study. <i>Human Pathology</i> , 2018, 72, 160-166.	1.1	40
28	Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy. <i>Clinical Cancer Research</i> , 2018, 24, 276-294.	3.2	32
29	Diseases of the Fallopian Tube and Paratubal Region. , 2018, , 1-66.		0
30	Germ Cell Tumors of the Ovary. , 2018, , 1-79.		0
31	Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study. <i>Cancer Prevention Research</i> , 2018, 11, 697-706.	0.7	47
32	Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: A nationwide case-control study. <i>Gynecologic Oncology</i> , 2017, 144, 571-576.	0.6	34
33	Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas. <i>American Journal of Surgical Pathology</i> , 2017, 41, 725-737.	2.1	57
34	Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma. <i>Human Pathology</i> , 2017, 68, 87-91.	1.1	19
35	The Utility of Sentinel Lymph Node Mapping in High-Grade Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1416-1421.	1.2	16
36	A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma. <i>Gynecologic Oncology</i> , 2017, 144, 174-180.	0.6	39

#	ARTICLE	IF	CITATIONS
37	Incidental Serous Tubal Intraepithelial Carcinoma and Non-Neoplastic Conditions of the Fallopian Tubes in Grossly Normal Adnexa: A Clinicopathologic Study of 388 Completely Embedded Cases. <i>International Journal of Gynecological Pathology</i> , 2016, 35, 423-429.	0.9	20
38	Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ system. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 408-436.	157.7	33
39	Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2016, 35, 48-55.	0.9	136
40	Invasive Complete Hydatidiform Moles. <i>International Journal of Gynecological Pathology</i> , 2016, 35, 134-141.	0.9	20
41	Distribution and case-fatality ratios by cell-type for ovarian carcinomas: A 22-year series of 562 patients with uniform current histological classification. <i>Gynecologic Oncology</i> , 2015, 136, 336-340.	0.6	26
42	Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Modern Pathology</i> , 2015, 28, 1101-1122.	2.9	164
43	GATA-3 Expression in Trophoblastic Tissues. <i>American Journal of Surgical Pathology</i> , 2015, 39, 101-108.	2.1	80
44	Incidental Serous Tubal Intraepithelial Carcinoma and Early Invasive Serous Carcinoma in the Nonprophylactic Setting. <i>American Journal of Surgical Pathology</i> , 2015, 39, 442-453.	2.1	71
45	Molecular analysis of ovarian mucinous carcinoma reveals different cell of origins. <i>Oncotarget</i> , 2015, 6, 22949-22958.	0.8	17
46	Mutational analysis of <i>BRAF</i> and <i>KRAS</i> in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants. <i>Journal of Pathology</i> , 2014, 232, 16-22.	2.1	52
47	<i>BRAF</i> Mutation Is Associated With a Specific Cell Type With Features Suggestive of Senescence in Ovarian Serous Borderline (Atypical Proliferative) Tumors. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1603-1611.	2.1	50
48	PAX8 Expression in Uterine Adenocarcinomas and Mesonephric Proliferations. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 492-499.	0.9	40
49	A Subset of Nondescript Axillary Lymph Node Inclusions Have the Immunophenotype of Endosalpingiosis. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1612-1617.	2.1	18
50	Papillary Cystadenoma of the Epididymis and Broad Ligament. <i>American Journal of Surgical Pathology</i> , 2014, 38, 713-718.	2.1	37
51	A Subset of Malignant Phyllodes Tumors Express p63 and p40. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1689-1696.	2.1	77
52	Origin and Pathogenesis of Pelvic (Ovarian, Tubal, and Primary Peritoneal) Serous Carcinoma. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2014, 9, 27-45.	9.6	142
53	Characteristics of hydatidiform moles: analysis of a prospective series with p57 immunohistochemistry and molecular genotyping. <i>Modern Pathology</i> , 2014, 27, 238-254.	2.9	117
54	A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002: Centralized pathology review and overall survival compared with the general population. <i>Gynecologic Oncology</i> , 2014, 134, 267-273.	0.6	56

#	ARTICLE	IF	CITATIONS
55	GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas. <i>Human Pathology</i> , 2013, 44, 1341-1349.	1.1	192
56	A subset of malignant phyllodes tumors harbors alterations in the Rb/p16 pathway. <i>Human Pathology</i> , 2013, 44, 2494-2500.	1.1	27
57	Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. <i>Histopathology</i> , 2013, 62, 44-58.	1.6	238
58	Clinically Occult Tubal and Ovarian High-grade Serous Carcinomas Presenting in Uterine Samples. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 433-443.	0.9	20
59	Characterization of Androgenetic/Biparental Mosaic/Chimeric Conceptions, Including Those With a Molar Component. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 199-214.	0.9	68
60	Borderline Atypical Ductal Hyperplasia/Low-grade Ductal Carcinoma In Situ on Breast Needle Core Biopsy Should Be Managed Conservatively. <i>American Journal of Surgical Pathology</i> , 2013, 37, 913-923.	2.1	27
61	Endocervical-type Mucinous Borderline Tumors are Related to Endometrioid Tumors Based on Mutation and Loss of Expression of ARID1A. <i>International Journal of Gynecological Pathology</i> , 2012, 31, 297-303.	0.9	74
62	Validation of an Algorithm for the Diagnosis of Serous Tubal Intraepithelial Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2012, 31, 243-253.	0.9	125
63	MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors. <i>Modern Pathology</i> , 2012, 25, 378-387.	2.9	67
64	Pax8 Expression in Uterine Malignant Mesodermal Mixed Tumor (Carcinosarcoma): Immunohistochemical Analysis of 37 Cases. <i>American Journal of Clinical Pathology</i> , 2012, 138, A023-A023.	0.4	0
65	Diagnostic Reproducibility of Hydatidiform Moles. <i>American Journal of Surgical Pathology</i> , 2012, 36, 443-453.	2.1	72
66	Diagnostic Reproducibility of Hydatidiform Moles. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1747-1760.	2.1	47
67	The Diagnosis of Endometrial Carcinomas With Clear Cells by Gynecologic Pathologists. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1107-1118.	2.1	69
68	TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma—evidence supporting the clonal relationship of the two lesions. <i>Journal of Pathology</i> , 2012, 226, 421-426.	2.1	332
69	A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: A population-based study of 4317 women diagnosed in Denmark 1978–2006. <i>Gynecologic Oncology</i> , 2012, 125, 655-660.	0.6	39
70	Ovarian Metastases of Pancreaticobiliary Tract Adenocarcinomas. <i>American Journal of Surgical Pathology</i> , 2011, 35, 276-288.	2.1	61
71	Papillary Tubal Hyperplasia. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1605-1614.	2.1	140
72	Diagnosis of Serous Tubal Intraepithelial Carcinoma Based on Morphologic and Immunohistochemical Features. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1766-1775.	2.1	151

#	ARTICLE	IF	CITATIONS
73	Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. <i>Modern Pathology</i> , 2011, 24, 1248-1253.	2.9	417
74	Relationship Between Molecular Subtype of Invasive Breast Carcinoma and Expression of Gross Cystic Disease Fluid Protein 15 and Mammaglobin. <i>American Journal of Clinical Pathology</i> , 2011, 135, 587-591.	0.4	65
75	Diseases of the Fallopian Tube and Paratubal Region. , 2011, , 529-578.		16
76	Germ Cell Tumors of the Ovary. , 2011, , 847-907.		16
77	Uterine Artery Embolization With Trisacryl Gelatin Microspheres in Women Treated For Leiomyomas: A Clinicopathologic Analysis of Alterations in Gynecologic Surgical Specimens. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 260-268.	0.9	4
78	Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin?. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1407-1416.	2.1	395
79	Precursor Lesions of High-Grade Serous Ovarian Carcinoma: Morphological and Molecular Characteristics. <i>Journal of Oncology</i> , 2010, 2010, 1-9.	0.6	64
80	Heterogeneity of Bcl-2 expression in metastatic breast carcinoma. <i>Modern Pathology</i> , 2010, 23, 1089-1096.	2.9	11
81	Metastatic and Miscellaneous Primary Tumors of the Ovary. , 2009, , 539-613.		10
82	Ovarian Low-grade and High-grade Serous Carcinoma. <i>Advances in Anatomic Pathology</i> , 2009, 16, 267-282.	2.4	477
83	HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. <i>BMC Cancer</i> , 2009, 9, 433.	1.1	175
84	The alternative lengthening of telomeres phenotype in breast carcinoma is associated with HER-2 overexpression. <i>Modern Pathology</i> , 2009, 22, 1423-1431.	2.9	45
85	Molecular Genotyping of Hydatidiform Moles. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 598-605.	1.2	74
86	Identification of the Most Sensitive and Robust Immunohistochemical Markers in Different Categories of Ovarian Sex Cord-stromal Tumors. <i>American Journal of Surgical Pathology</i> , 2009, 33, 354-366.	2.1	175
87	Diagnosis and Subclassification of Hydatidiform Moles Using p57 Immunohistochemistry and Molecular Genotyping: Validation and Prospective Analysis in Routine and Consultation Practice Settings With Development of an Algorithmic Approach. <i>American Journal of Surgical Pathology</i> , 2009, 33, 805-817.	2.1	111
88	Defining the Cut Point Between Low-grade and High-grade Ovarian Serous Carcinomas. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1220-1224.	2.1	75
89	Endocervical Adenocarcinomas With Prominent Endometrial or Endomyometrial Involvement Simulating Primary Endometrial Carcinomas. <i>American Journal of Surgical Pathology</i> , 2009, 33, 914-924.	2.1	77
90	Most Basal-like Breast Carcinomas Demonstrate the Same Rb ⁺ /p16 ⁺ Immunophenotype as the HPV-related Poorly Differentiated Squamous Cell Carcinomas Which They Resemble Morphologically. <i>American Journal of Surgical Pathology</i> , 2009, 33, 163-175.	2.1	106

#	ARTICLE	IF	CITATIONS
91	The Superficial Margin of the Skin-Sparing Mastectomy for Breast Carcinoma: Factors Predicting Involvement and Efficacy of Additional Margin Sampling. <i>Annals of Surgical Oncology</i> , 2008, 15, 1330-1340.	0.7	52
92	Endocervical Adenocarcinomas With Ovarian Metastases. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1835-1853.	2.1	157
93	Distinction of Primary and Metastatic Mucinous Tumors Involving the Ovary: Analysis of Size and Laterality Data by Primary Site With Reevaluation of an Algorithm for Tumor Classification. <i>American Journal of Surgical Pathology</i> , 2008, 32, 128-138.	2.1	163
94	SF-1 is a Diagnostically Useful Immunohistochemical Marker and Comparable to Other Sex Cord-Stromal Tumor Markers for the Differential Diagnosis of Ovarian Sertoli Cell Tumor. <i>International Journal of Gynecological Pathology</i> , 2008, 27, 507-514.	0.9	72
95	Subdividing Ovarian and Peritoneal Serous Carcinoma Into Moderately Differentiated and Poorly Differentiated Does not Have Biologic Validity Based on Molecular Genetic and In Vitro Drug Resistance Data. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1667-1674.	2.1	42
96	Ovarian Metastases of Appendiceal Tumors With Goblet Cell Carcinoidlike and Signet Ring Cell Patterns. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1502-1511.	2.1	83
97	p16 Expression in Primary Ovarian Mucinous and Endometrioid Tumors and Metastatic Adenocarcinomas in the Ovary. <i>American Journal of Surgical Pathology</i> , 2007, 31, 653-663.	2.1	88
98	Diagnostic Utility of WT1 Immunostaining in Ovarian Sertoli Cell Tumor. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1378-1386.	2.1	48
99	Estrogen Receptor \pm and Progesterone Receptor Expression in Ovarian Adult Granulosa Cell Tumors and Sertoli-Leydig Cell Tumors. <i>International Journal of Gynecological Pathology</i> , 2007, 26, 375-382.	0.9	50
100	Immunohistochemical Analysis of Sox9 in Ovarian Sertoli Cell Tumors and Other Tumors in the Differential Diagnosis. <i>International Journal of Gynecological Pathology</i> , 2007, 26, 1-9.	0.9	22
101	Comparative Analysis of Alternative and Traditional Immunohistochemical Markers for the Distinction of Ovarian Sertoli Cell Tumor From Endometrioid Tumors and Carcinoid Tumor. <i>American Journal of Surgical Pathology</i> , 2007, 31, 255-266.	2.1	72
102	Ovarian Mucinous Tumors Associated With Mature Cystic Teratomas. <i>American Journal of Surgical Pathology</i> , 2007, 31, 854-869.	2.1	169
103	Utero-Ovarian Anastomosis: Histopathologic Correlation after Uterine Artery Embolization with or without Ovarian Artery Embolization. <i>Journal of Vascular and Interventional Radiology</i> , 2007, 18, 31-39.	0.2	24
104	Effects of Utero-ovarian Anastomoses on Basal Follicle-stimulating Hormone Level Change after Uterine Artery Embolization with Tris-acryl Gelatin Microspheres. <i>Journal of Vascular and Interventional Radiology</i> , 2006, 17, 965-971.	0.2	44
105	Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma. <i>Human Pathology</i> , 2006, 37, 1169-1175.	1.1	38
106	Current Problems With Staging Lymphomas Involving the Ovary. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1202-1203.	2.1	2
107	Ovarian Atypical Proliferative (Borderline) Mucinous Tumors: Gastrointestinal and Seromucinous (Endocervical-Like) Types are Immunophenotypically Distinctive. <i>International Journal of Gynecological Pathology</i> , 2006, 25, 83-89.	0.9	96
108	Cytokeratins 7 and 20 in Primary and Secondary Mucinous Tumors of the Ovary: Analysis of Coordinate Immunohistochemical Expression Profiles and Staining Distribution in 179 Cases. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1130-1139.	2.1	186

#	ARTICLE	IF	CITATIONS
109	Distinction of Primary Ovarian Mucinous Tumors and Mucinous Tumors Metastatic to the Ovary. , 2006, 11, 18-30.		9
110	Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Modern Pathology, 2006, 19, 97-105.	2.9	114
111	Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Modern Pathology, 2006, 19, 1421-1428.	2.9	174
112	Separate Cavity Margin Sampling at the Time of Initial Breast Lumpectomy Significantly Reduces the Need for Reexcisions. American Journal of Surgical Pathology, 2005, 29, 1625-1632.	2.1	118
113	Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14004-14009.	3.3	135
114	Nuclear size distinguishes low- from high-grade ovarian serous carcinoma and predicts outcome. Human Pathology, 2005, 36, 1049-1054.	1.1	30
115	Signet-ring Stromal Tumor of the Ovary: Clinicopathologic Analysis and Comparison With Krukenberg Tumor. International Journal of Gynecological Pathology, 2004, 23, 45-51.	0.9	80
116	Immunohistochemical Staining for Ki-67 and p53 Helps Distinguish Endometrial Arias-Stella Reaction from High-Grade Carcinoma, Including Clear Cell Carcinoma. International Journal of Gynecological Pathology, 2004, 23, 223-233.	0.9	66
117	Comparative Immunohistochemical Analysis of Granulosa and Sertoli Components in Ovarian Sex Cord-Stromal Tumors with Mixed Differentiation: Potential Implications for Derivation of Sertoli Differentiation in Ovarian Tumors. International Journal of Gynecological Pathology, 2004, 23, 151-161.	0.9	31
118	Proliferative Mucinous Lesions of the Endometrium: Analysis of Existing Criteria for Diagnosing Carcinoma in Biopsies and Curettings. International Journal of Surgical Pathology, 2003, 11, 261-270.	0.4	47
119	Perivascular Epithelioid Cell Tumor ('PEComa') of the Uterus. American Journal of Surgical Pathology, 2002, 26, 1-13.	2.1	309
120	Immunohistochemical Analysis of Clear Cell Carcinoma of the Gynecologic Tract. International Journal of Gynecological Pathology, 2001, 20, 252-259.	0.9	124
121	Non-Hodgkin's Lymphoma Involving the Gynecologic Tract: A Review of 88 Cases. Advances in Anatomic Pathology, 2001, 8, 200-217.	2.4	97
122	Ovarian Non-Hodgkin's Lymphoma: A Clinicopathologic Study of Eight Primary Cases. Modern Pathology, 2001, 14, 1093-1099.	2.9	133
123	Non-Hodgkin's Lymphoma Involving the Vulva. International Journal of Gynecological Pathology, 2000, 19, 236-242.	0.9	47
124	Endometrial Carcinoma and Non-Hodgkin's Lymphoma Involving the Female Genital Tract: A Report of Three Cases. International Journal of Gynecological Pathology, 2000, 19, 133-138.	0.9	17
125	Non-Hodgkin's Lymphoma Involving the Vagina. American Journal of Surgical Pathology, 2000, 24, 719-725.	2.1	50
126	Immunohistochemical Determination of HER-2/neu Expression in Invasive Breast Carcinoma. American Journal of Clinical Pathology, 2000, 113, 669-674.	0.4	28

#	ARTICLE	IF	CITATIONS
127	Non-Hodgkin's Lymphomas Involving the Uterus: A Clinicopathologic Analysis of 26 Cases. <i>Modern Pathology</i> , 2000, 13, 19-28.	2.9	165
128	Primary Vulvar and Vaginal Extraosseous Ewing's Sarcoma/Peripheral Neuroectodermal Tumor: Diagnostic Confirmation with CD99 Immunostaining and Reverse Transcriptase-Polymerase Chain Reaction. <i>International Journal of Gynecological Pathology</i> , 2000, 19, 103-109.	0.9	52
129	Vulvar Hypertrophy With Lymphedema. <i>Archives of Pathology and Laboratory Medicine</i> , 2000, 124, 1697-1699.	1.2	30